N-Vector

N-Vector is a pre-clinical stage biotechnology company focused on developing non-viral gene delivery platforms to treat cancer and other complex diseases. The company leverages proprietary nanoparticle technology, including Liposome-Polycation-DNA (LPD) structures, to deliver therapeutic nucleic acids such as DNA, mRNA, and siRNA directly to target cells. This approach is designed to minimize the immune response typically associated with viral vectors while allowing for high-capacity cargo delivery and precise targeting of the tumor microenvironment. N-Vector's pipeline primarily targets oncogenic drivers and tumor suppressor pathways to provide next-generation genetic medicines.